×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARMP – armata pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARMP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
07:00 am
armp
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Medium
Report
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
11/13
01:09 am
armp
Armata Pharmaceuticals GAAP EPS of -$0.74, revenue of $1.16M [Seeking Alpha]
Low
Report
Armata Pharmaceuticals GAAP EPS of -$0.74, revenue of $1.16M [Seeking Alpha]
11/12
04:05 pm
armp
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Low
Report
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
11/10
07:11 am
armp
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California [Yahoo! Finance]
Medium
Report
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California [Yahoo! Finance]
11/10
07:00 am
armp
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Medium
Report
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
10/22
11:10 am
armp
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
High
Report
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
10/14
07:20 am
armp
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ [Yahoo! Finance]
Low
Report
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ [Yahoo! Finance]
10/14
07:00 am
armp
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Low
Report
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
MISS
Report
-6.4%
armata pharmaceuticals, inc.
8/12/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
MISS
Report
1.2%
armata pharmaceuticals, inc.
5/14/2025
04:05 pm
ARMP
armata pharmaceuticals, inc.
BEAT
Report
1.4%
armata pharmaceuticals, inc.
3/20/2025
05:56 pm
ARMP
armata pharmaceuticals, inc.
BEAT
Report
-10.9%
armata pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
05:16 pm
armp
Form 424B5 Armata Pharmaceuticals,
High
Report
Form 424B5 Armata Pharmaceuticals,
11/12
04:17 pm
armp
Form 10-Q Armata Pharmaceuticals, For: Sep 30
Medium
Report
Form 10-Q Armata Pharmaceuticals, For: Sep 30
11/12
04:11 pm
armp
Form 8-K Armata Pharmaceuticals, For: Nov 12
Medium
Report
Form 8-K Armata Pharmaceuticals, For: Nov 12
10/22
11:16 am
armp
Form 8-K Armata Pharmaceuticals, For: Oct 22
High
Report
Form 8-K Armata Pharmaceuticals, For: Oct 22
9/11
06:01 am
armp
Form 8-K Armata Pharmaceuticals, For: Sep 10
Low
Report
Form 8-K Armata Pharmaceuticals, For: Sep 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/28
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs
70.3%
5/28 Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient 45.0%
5/9 C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. 16.0%
10/11 Form PRE 14A Armata Pharmaceuticals, For: Dec 10 11.8%
3/18 Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation 10.9%
5/16 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Varnum Brian 6.3%
1/29 Form 8-K Armata Pharmaceuticals, For: Jan 27 4.5%
6/24 Form 8-K Armata Pharmaceuticals, For: Jun 24 4.3%
1/9 Form S-1/A Armata Pharmaceuticals, 4.3%
3/30 Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. 4.1%
5/28 Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient 45.0%
5/9 C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc. 16.0%
10/11 Form PRE 14A Armata Pharmaceuticals, For: Dec 10 11.8%
3/18 Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation 10.9%
5/16 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Varnum Brian 6.3%
1/29 Form 8-K Armata Pharmaceuticals, For: Jan 27 4.5%
6/24 Form 8-K Armata Pharmaceuticals, For: Jun 24 4.3%
1/9 Form S-1/A Armata Pharmaceuticals, 4.3%
3/30 Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. 4.1%
TOP News Decliners
12/20
Form S-1 Armata Pharmaceuticals,
-12.0%
5/20 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Delta Dental of Wisconsin, Inc. -10.7%
11/12 Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update -9.7%
2/21 Form PRE 14A Armata Pharmaceuticals, For: Feb 21 -8.3%
3/30 Form 8-K Armata Pharmaceuticals, For: Mar 26 -6.9%
5/14 Form 8-K Armata Pharmaceuticals, For: May 14 -6.2%
8/14 Q2/2019 6/30/2019 EPS -0.690 ZacksConsensus -0.290 ActVsEst (0.400) - Miss -6.1%
6/3 Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada -4.8%
7/24 Form 8-K/A Armata Pharmaceuticals, For: May 14 -4.0%
1/13 Form SC 13G/A Armata Pharmaceuticals, Filed by: LILLY ENDOWMENT INC -3.8%
5/20 Form 3 Armata Pharmaceuticals, For: May 09 Filed by: Delta Dental of Wisconsin, Inc. -10.7%
11/12 Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update -9.7%
2/21 Form PRE 14A Armata Pharmaceuticals, For: Feb 21 -8.3%
3/30 Form 8-K Armata Pharmaceuticals, For: Mar 26 -6.9%
5/14 Form 8-K Armata Pharmaceuticals, For: May 14 -6.2%
8/14 Q2/2019 6/30/2019 EPS -0.690 ZacksConsensus -0.290 ActVsEst (0.400) - Miss -6.1%
6/3 Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada -4.8%
7/24 Form 8-K/A Armata Pharmaceuticals, For: May 14 -4.0%
1/13 Form SC 13G/A Armata Pharmaceuticals, Filed by: LILLY ENDOWMENT INC -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: